AstraZeneca's Results Provide a Mixed Picture -- Market Talk

Dow Jones
Apr 29, 2025

0804 GMT - AstraZeneca posted higher profit and sales in the first quarter, but its revenue missed consensus due to generics competition, Intron Health analysts say in a note. The British pharma giant reiterated its 2025 outlook. The updates that AstraZeneca provided related to its ongoing anti-corruption probes in China seem minor in scope, they say. Shares are down 3.9% at 10,116 pence. (helena.smolak@wsj.com)

 

(END) Dow Jones Newswires

April 29, 2025 04:04 ET (08:04 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10